目的 評價芪藶強(qiáng)心膠囊聯(lián)合米力農(nóng)治療慢性心力衰竭的臨床療效。方法 選取2018年1月—2020年6月內(nèi)蒙古包鋼醫(yī)院慢性心力衰竭患者140例作為研究對象，隨機(jī)將患者分為對照組和觀察組，每組各70例。對照組以米力農(nóng)注射液0.5 μg/（kg·min）持續(xù)泵入72 h，繼以0.5 μg/（kg·min）每日1次泵入，共4 d。觀察組在對照組治療基礎(chǔ)上口服芪藶強(qiáng)心膠囊，3粒/次，3次/d。兩組治療療程均為7 d。觀察兩組患者的臨床療效，同時比較兩組治療前后的腦鈉肽（BNP）、N末端B型利鈉肽原（NT-proBNP）、高敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-6（IL-6）、胱抑素C（Cys-C）水平、左室射血分?jǐn)?shù)（LVEF）和左室舒張末期內(nèi)徑（LVED）。結(jié)果 治療后，對照組和觀察組的總有效率分別為85.7%和97.1%；兩組的總有效率差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組BNP、NT-proBNP、hs-CRP、IL-6、Cys-C及LVED水平均顯著下降，LVEF顯著升高（P<0.05），且觀察組上述指標(biāo)顯著優(yōu)于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合米力農(nóng)治療慢性心力衰竭療效顯著，且耐受性較好，具有臨床應(yīng)用及推廣價值。

Objective To evaluate the clinical effect of Qiliqiangxin Capsules combined with milrinone in treatment of chronic heart failure. Methods A total of 140 patients with chronic heart failure from January 2018 to June 2020 in Baogang Hospital of Inner Mongolia were selected as the research subjects, patients were randomly divided into control group and observation group, with 70 patients in each group. Patients in the control group were continuously pumped with Milrinone Injection of 0.5 g/(kg·min) for 72 h, and continued to be pumped every once for 4 days. Patients in the observation group were po administered with Qiliqiangxin Capsules on the basis of control group, 3 grains/time, three times daily. The course of treatment in both groups was 7 days. The clinical efficacy of two groups was observed, and the levels of BNP, NT-proBNP, hs-CRP, IL-6, Cys-C, and LVEF, LVED before and after treatment were compared. Results After treatment, the total effective rate of the control group and the observation group was 85.7% and 97.1%, respectively, the total effective rate difference between two groups was statistically significant (P<0.05). After treatment, the levels of BNP, NT-proBNP, hs-CRP, IL-6, Cys-C, and LVED in two groups were significantly decreased, but LVEF was significantly increased (P<0.05). After treatment, the above indexes in the observation group were significantly better than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Qiliqiangxin Capsules combined with milrinone in treatment of chronic heart failure is effective, and tolerability is good, with clinical application and promotion value.

R972